Aratana Awarded “Best Pipeline 2014” by Animal Pharm

Aratana Therapeutics, today announced it has received the “Best Pipeline 2014” award from Animal Pharm, a leading online business intelligence service for the animal health sector.  Animal Pharm noted that Aratana was selected for the award based on “the depth of its pipeline and the potentially lucrative opportunity the firm faces.”

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, commented, “The ‘Best Pipeline 2014’ award from Animal Pharm is very gratifying for Aratana as it highlights our ability to take a truly unique vision – transforming the pet therapeutics industry through the development and commercialization of innovative biopharmaceutical products – and make it a reality.  Today, Aratana has a diversified pipeline consisting of biologics and small molecules targeting multiple therapeutic indications for dogs and cats, each of which represents a potential breakthrough for veterinary medicine. Looking ahead, we are focused on advancing our pipeline and commercial operations, while continuing to expand our portfolio via potential in-licensing and acquisition opportunities.”

Aratana’s diversified portfolio consists of more than 18 therapeutic candidates. Representative of the company’s progress and potential for continued growth, in the past month, Aratana has announced important advances with three of its products:

  • AT-004:  Aratana received a full license from the U.S. Department of Agriculture (USDA) for the company’s canine-specific monoclonal antibody targeting CD20 as an aid in the treatment of B-cell lymphoma in dogs. Aratana believes that this represents the only full license for a species-specific monoclonal antibody within the animal health industry.  AT-004 is exclusively partnered with a third-party for commercialization in the U.S. and Canada
  • AT-001:  Aratana announced positive results from its pivotal field study of AT-001 (Grapiprant), the company’s innovative drug for treating pain in dogs with osteoarthritis.  In the study, dogs receiving AT-001 demonstrated improvements in pain assessment scores that were statistically significant compared to placebo (p<0.05) at a once-daily oral dose.  Aratana expects to commence commercialization upon FDA approval, which Aratana anticipates in 2016
  • AT-003:  Aratana initiated the pivotal field effectiveness study for AT-003, the company’s innovative drug for treating post-surgical pain in dogs. AT-003 is an extended release injectable formulation of bupivacaine, a drug licensed from Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX)

Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner.

Recent News Posts

View All